Erleada (apalutamide) vs Entadfi (finasteride and tadalafil)

Erleada (apalutamide) is an androgen receptor inhibitor specifically approved for the treatment of non-metastatic castration-resistant prostate cancer, working by blocking the effect of androgens to slow the growth of prostate cancer. Entadfi, on the other hand, combines finasteride, a 5-alpha-reductase inhibitor that reduces the size of the prostate gland, with tadalafil, which is used to treat erectile dysfunction and alleviate urinary symptoms. When deciding between the two, a patient must consider their specific condition: Erleada is for cancer management, whereas Entadfi is used to treat benign prostatic hyperplasia (BPH) symptoms and associated erectile dysfunction, and is not indicated for prostate cancer treatment.

Difference between Erleada and Entadfi

Metric	Erleada (apalutamide)	Entadfi (finasteride and tadalafil)
Generic name	Apalutamide	Finasteride and Tadalafil
Indications	Non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC)	Benign prostatic hyperplasia (BPH)
Mechanism of action	Androgen receptor inhibitor	Finasteride: 5-alpha-reductase inhibitor, Tadalafil: Phosphodiesterase type 5 (PDE5) inhibitor
Brand names	Erleada	Entadfi
Administrative route	Oral	Oral
Side effects	Fatigue, hypertension, rash, diarrhea, nausea, weight loss, arthralgia, falls, hot flush, decreased appetite, fractures, peripheral edema	Dizziness, hypotension, headache, flushing, nasal congestion, back pain, dyspepsia, pain in extremity
Contraindications	Pregnancy, severe hepatic impairment	Hypersensitivity to finasteride or tadalafil, concomitant nitrates use, severe renal impairment
Drug class	Antiandrogen	Finasteride: 5-alpha-reductase inhibitor, Tadalafil: PDE5 inhibitor
Manufacturer	Janssen Pharmaceuticals	Teva Pharmaceuticals

Efficacy

Erleada (Apalutamide) for Prostate Cancer

Erleada, with the active ingredient apalutamide, is a medication approved for the treatment of prostate cancer. Specifically, it is indicated for patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The efficacy of Erleada was demonstrated in a pivotal clinical trial known as SPARTAN, which showed that apalutamide significantly extended metastasis-free survival compared to placebo. Patients treated with Erleada had a median metastasis-free survival of over two years longer than those who received a placebo, marking a substantial improvement in delaying the progression of prostate cancer in this patient population.

In addition to its use in nmCRPC, Erleada has also been approved for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). Clinical trials have indicated that when used in combination with androgen deprivation therapy (ADT), apalutamide can improve survival outcomes for men with this type of prostate cancer. The efficacy in this setting was supported by the results of the TITAN study, which showed that the combination of Erleada and ADT significantly reduced the risk of death compared to ADT alone.

Entadfi (Finasteride and Tadalafil) for Prostate Cancer

Entadfi is a combination medication that contains finasteride and tadalafil, which is not specifically approved for the treatment of prostate cancer. Finasteride is primarily used to treat benign prostatic hyperplasia (BPH), and it works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), a hormone that can contribute to prostate growth. While finasteride has been studied for its potential role in prostate cancer prevention, it is not a standard treatment for prostate cancer itself.

Tadalafil, the other component of Entadfi, is a phosphodiesterase type 5 (PDE5) inhibitor commonly used to treat erectile dysfunction and the symptoms of BPH. Its role in the management of prostate cancer is not established, and there is no significant evidence to suggest that tadalafil alone or in combination with finasteride is effective for the treatment of prostate cancer. Therefore, while Entadfi may have applications in managing symptoms associated with BPH, its efficacy in the context of prostate cancer has not been substantiated by clinical trials specific to this disease.

Regulatory Agency Approvals

Erleada

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Entadfi

Food and Drug Administration (FDA), USA

Access Erleada or Entadfi today

If Erleada or Entadfi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Erleada

Buy Entadfi

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: